Genetown
Filter News
Found 51,901 articles
-
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.
-
Shares of newly dubbed Sesen Bio (formerly Eleven Biotherapeutics) have plunged 23 percent after the company released positive, three-month data from its ongoing Phase III high-grade non-muscle invasive bladder cancer (NMIBC) trial.
-
Hemophilia B patients have some good news to cheer. Data suggests that uniQure’s AAV5 gene therapy may be viable treatments for 97 percent of patients. However, uniQure wasn’t the only company touting positive news in the treatment of hemophilia.
-
Alivio Therapeutics Announces Issuance of Two U.S. Patents Broadly Covering Compositions of Matter for Inflammation-Targeting Technology Platform
5/22/2018
Alivio Therapeutics, an affiliate of PureTech Health plc (LSE: PRTC) developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent Nos. 9,962,339 and 9,974,859, related to the Company’s inflammation-targeting technology platform.
-
OmniGuide Surgical Announces Commercial Launch of C-LAS Line of Sight CO2 Laser System
5/22/2018
OmniGuide Holdings, Inc., the parent company of OmniGuide Surgical, announced today the full commercial release of the C-LAS Line of Sight CO2 Laser System. The C-LAS Laser System is the latest addition to OmniGuide’s trusted laser portfolio, offering the same CO2 tissue sparing properties as its Intelliguide Fiber Enabled Laser System, but differing in the manner in which the laser energy is delivered.
-
Anuncia Announces Successful First-in-Human Use of the Alivio ReFlow™ Ventricular System for Treatment of Hydrocephalus
5/22/2018
- Novel product provides qualified clinicians with the option of non-invasive retrograde flushing of the ventricular catheter, to unblock occluded inlet holes or open a relief membrane to restore or increase cerebrospinal fluid (CSF) flow in a non-flowing shunt - According to The Hydrocephalus Association, at least 50 percent of patients implanted with shunts suffer from shunt failures and blockages within two years, requiring repeated revision surgeries
-
Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension
5/22/2018
PULSAR trial expands Acceleron’s pipeline into pulmonary disease
-
MaxQ-AI Receives CE Mark Approval for Accipio™Ix Intracranial Hemorrhage Artificial Intelligence Software Platform
5/22/2018
MaxQ Artificial Intelligence (MaxQ-AI), a global artificial intelligence (AI) healthcare company, today announced that it has received the CE Mark approval for its revolutionary Accipio software platform.
-
uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies
5/22/2018
uniQure N.V. presented data showing successful liver transduction with the AAV5 vector in both non-human primates and humans with pre-existing anti-AAV5 neutralizing antibodies (NABs).
-
Alzheon to Make Presentations at Upcoming Industry and Investor Conferences
5/22/2018
Keynote at Drug Discovery Innovation Programme and Company Presentation at JMP Securities Life Sciences Conference
-
TapImmune Expands Scientific Advisory Board with Cancer Immunotherapy Pioneers James P. Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., from the MD Anderson Cancer Center
5/22/2018
TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that it has expanded its recently formed Scientific Advisory Board (SAB) and will support the continued clinical development of the Company's transformative, non-genetically engineered, multi-antigen T cell therapy platform.
-
Evotec and Celgene Enter into Strategic Oncology Partnership
5/22/2018
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that Evotec and Celgene Corporation ("Celgene") have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology.
-
Health Outcomes & Technology Company OM1 Closes $21 Million Series B Financing And Expands Product Offerings
5/22/2018
Polaris Partners led the investment and Dave Barrett joins the Board of Directors as the team expands its intelligent data cloud and curated registries for measuring, comparing and predicting health outcomes
-
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
-
Deciphera Pharmaceuticals Expands Board with the Election of Mr. Steven L. Hoerter as a Director
5/21/2018
Steve Hoerter, Chief Commercial Officer at Agios Pharmaceuticals, Inc., Elected to Board of Directors
-
ImmusanT Expands Management Team to Strengthen Financial Operations and Accelerate Clinical Development
5/21/2018
-- Kristin M. Neff joins as VP, Clinical Operations and Project Management – -- Joyce A. Pinkham joins as VP, Program Management – -- Jonathan Yeadon joins as Director, Finance –
-
Bioverativ Presents Preliminary Phase 1/2a Data on BIVV001, the First Factor VIII Therapy to Break Through the VWF Half-Life Ceiling in Hemophilia A
5/21/2018
BIVV001 demonstrates unprecedented half-life of 37 hours with high factor VIII activity of 5.6% at seven days following a single low dose in late-breaking presentation at WFH 2018 World Congress Bioverativ is now exploring twice-a-month dosing with BIVV001, which could transform the treatment paradigm in hemophilia A
-
coreHEM Publishes Core Outcome Set for Hemophilia Clinical Trials; Prepares to Launch Next Phase of Work
5/21/2018
The coreHEM initiative has announced the publication of a core outcome set for clinical trials of gene therapy in hemophilia.
-
Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three Months in Carcinoma in Situ Patients
5/21/2018
May 21, 2018 18:15 UTC Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three Months in Carcinoma in Situ Patients Sesen Bio (Formally Eleven Biotherapeutics) Reports Positive, Three-Month Data from VISTA Trial of Vicinium™ in High-Grade NMIBC Data Presented During Plenary Session at American Urological Association Annual Meeting Company to Host Co
-
Iora Health Raises $100 Million in Series E Financing
5/21/2018
Funding to fuel further development of technology and care model and growth in current and new markets